Cargando…
Variation of butyrate production in the gut microbiome in type 2 diabetes patients
BACKGROUND: Diabetes mellitus type 2 is a common disease that poses a challenge to the healthcare system. The disease is very often diagnosed late. A better understanding of the relationship between the gut microbiome and type 2 diabetes can support early detection and form an approach for therapies...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397123/ https://www.ncbi.nlm.nih.gov/pubmed/36780038 http://dx.doi.org/10.1007/s10123-023-00324-6 |
_version_ | 1785083851211538432 |
---|---|
author | Siptroth, Julienne Moskalenko, Olga Krumbiegel, Carsten Ackermann, Jörg Koch, Ina Pospisil, Heike |
author_facet | Siptroth, Julienne Moskalenko, Olga Krumbiegel, Carsten Ackermann, Jörg Koch, Ina Pospisil, Heike |
author_sort | Siptroth, Julienne |
collection | PubMed |
description | BACKGROUND: Diabetes mellitus type 2 is a common disease that poses a challenge to the healthcare system. The disease is very often diagnosed late. A better understanding of the relationship between the gut microbiome and type 2 diabetes can support early detection and form an approach for therapies. Microbiome analysis offers a potential opportunity to find markers for this disease. Next-generation sequencing methods can be used to identify the bacteria present in the stool sample and to generate a microbiome profile through an analysis pipeline. Statistical analysis, e.g., using Student’s t-test, allows the identification of significant differences. The investigations are not only focused on single bacteria, but on the determination of a comprehensive profile. Also, the consideration of the functional microbiome is included in the analyses. The dataset is not from a clinical survey, but very extensive. RESULTS: By examining 946 microbiome profiles of diabetes mellitus type 2 sufferers (272) and healthy control persons (674), a large number of significant genera (25) are revealed. It is possible to identify a large profile for type 2 diabetes disease. Furthermore, it is shown that the diversity of bacteria per taxonomic level in the group of persons with diabetes mellitus type 2 is significantly reduced compared to a healthy control group. In addition, six pathways are determined to be significant for type 2 diabetes describing the fermentation to butyrate. These parameters tend to have high potential for disease detection. CONCLUSIONS: With this investigation of the gut microbiome of persons with diabetes type 2 disease, we present significant bacteria and pathways characteristic of this disease. |
format | Online Article Text |
id | pubmed-10397123 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-103971232023-08-04 Variation of butyrate production in the gut microbiome in type 2 diabetes patients Siptroth, Julienne Moskalenko, Olga Krumbiegel, Carsten Ackermann, Jörg Koch, Ina Pospisil, Heike Int Microbiol Research BACKGROUND: Diabetes mellitus type 2 is a common disease that poses a challenge to the healthcare system. The disease is very often diagnosed late. A better understanding of the relationship between the gut microbiome and type 2 diabetes can support early detection and form an approach for therapies. Microbiome analysis offers a potential opportunity to find markers for this disease. Next-generation sequencing methods can be used to identify the bacteria present in the stool sample and to generate a microbiome profile through an analysis pipeline. Statistical analysis, e.g., using Student’s t-test, allows the identification of significant differences. The investigations are not only focused on single bacteria, but on the determination of a comprehensive profile. Also, the consideration of the functional microbiome is included in the analyses. The dataset is not from a clinical survey, but very extensive. RESULTS: By examining 946 microbiome profiles of diabetes mellitus type 2 sufferers (272) and healthy control persons (674), a large number of significant genera (25) are revealed. It is possible to identify a large profile for type 2 diabetes disease. Furthermore, it is shown that the diversity of bacteria per taxonomic level in the group of persons with diabetes mellitus type 2 is significantly reduced compared to a healthy control group. In addition, six pathways are determined to be significant for type 2 diabetes describing the fermentation to butyrate. These parameters tend to have high potential for disease detection. CONCLUSIONS: With this investigation of the gut microbiome of persons with diabetes type 2 disease, we present significant bacteria and pathways characteristic of this disease. Springer International Publishing 2023-02-13 2023 /pmc/articles/PMC10397123/ /pubmed/36780038 http://dx.doi.org/10.1007/s10123-023-00324-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Siptroth, Julienne Moskalenko, Olga Krumbiegel, Carsten Ackermann, Jörg Koch, Ina Pospisil, Heike Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title | Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title_full | Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title_fullStr | Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title_full_unstemmed | Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title_short | Variation of butyrate production in the gut microbiome in type 2 diabetes patients |
title_sort | variation of butyrate production in the gut microbiome in type 2 diabetes patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397123/ https://www.ncbi.nlm.nih.gov/pubmed/36780038 http://dx.doi.org/10.1007/s10123-023-00324-6 |
work_keys_str_mv | AT siptrothjulienne variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients AT moskalenkoolga variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients AT krumbiegelcarsten variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients AT ackermannjorg variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients AT kochina variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients AT pospisilheike variationofbutyrateproductioninthegutmicrobiomeintype2diabetespatients |